Impact of 18F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle

BJU International

Volumn 112, Issue 6, 2013, Pages 729-734

  Mertens, Laura S ^a   Fioole Bruining, Annemarie ^a   Vegt, Erik ^a   Vogel, Wouter V ^a   Van Rhijn, Bas W ^a   Horenblas, Simon ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

computed tomography; disease management; neoplasm staging; positron emission tomography; transitional cell carcinoma; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYSTECTOMY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PET SCANNER; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR INVASION;

COMPUTED TOMOGRAPHY; DISEASE MANAGEMENT; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TRANSITIONAL CELL CARCINOMA; URINARY BLADDER NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 84884291325     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12109     Document Type: Article

References (19)

1. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-1018
2. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT,. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003; 169: 105-109
3. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111-1116
4. Ghoneim MA, el Mekresh MM, el Baz MA, el Attar IA, Ashamallah A,. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997; 158: 393-399
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866
6. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E,. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155: 1903-1906
7. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354: 533-540
8. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-205
9. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK,. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-2177
10. Apolo AB, Riches J, Schoder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010; 28: 3973-3978
11. Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27: 4314-4320
12. Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 2011; 81: 2411-2416
13. Yang Z, Pan L, Cheng J, et al. Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer. Int J Urol 2012; 19: 639-644
14. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
15. Sobin LH, Gospodarowicz MK, Wittekind CH,. TNM Classification of Malignant Tumours, 7th edn. Oxford: Wiley-Blackwell, 2009
16. Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE,. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007; 48: 764-770
17. Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y,. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 2010; 106: 658-663
18. Lee ST, Lawrentschuk N, Scott AM,. PET in prostate and bladder tumors. Semin Nucl Med 2012; 42: 231-246
19. Lawrentschuk N,. Role of positron emission tomography in urological oncology. BJU Int 2010; 106: 1593-1594